Brain cancer breakthrough? new drug combo trial offers hope for deadly recurrence
NCT ID NCT07297212
Summary
This study is testing the safety and effectiveness of a new drug called pumitamig, both alone and in combination with other cancer drugs, for adults whose aggressive brain cancer (glioblastoma) has returned after initial treatment. The goal is to see if these treatments can shrink tumors and control the disease. About 75 people will participate to help researchers find better options for this difficult-to-treat condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital, Capital Medical University
RECRUITINGBeijing, 100070, China
Conditions
Explore the condition pages connected to this study.